Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study
Evoke Pharma, Inc. (EVOK)
Last evoke pharma, inc. earnings: 11/7 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
evokepharmainc.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
SOLANA BEACH, Calif. and CHICAGO, June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced positive findings from a second market research study conducted for GIMOTI® (metoclopramide) nasal spray. The study aimed to gather further market insights on the perception of GIMOTI in the GI community and follows the initial market research study conducted in December 2020. The Company will discuss the findings in roundtable discussions at the upcoming GI ReConnect Conference, a leadership summit for sharing the most current information on GI health, being held on June 18-19th in Napa Valley, CA. In May 2021, Evoke’s commercialization partner, EVERSANA, conducted the GIMOTI Awareness, Trial, Usage (ATU) Study, a quantitative survey designed to measure physician awareness, trial,
Show less
Read more
Impact Snapshot
Event Time:
EVOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVOK alerts
High impacting Evoke Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
EVOK
News
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 MedicationsGlobeNewswire
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EVOK
Sec Filings
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- EVOK's page on the SEC website